{
    "organizations": [],
    "uuid": "2ed40bc5076a8c03a06b84ec76deab53b05a52c0",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-albireo-pharma-says-elobixibat-app/brief-albireo-pharma-says-elobixibat-approved-in-japan-for-treatment-of-chronic-constipation-idUSFWN1PE0SH",
    "ord_in_thread": 0,
    "title": "BRIEF-Albireo Pharma Says Elobixibat Approved In Japan For Treatment Of Chronic Constipation",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 19 (Reuters) - Albireo Pharma Inc:\n* ALBIREO TO RECEIVE MORE THAN $55 MILLION(1) IN NONDILUTIVE CASH PAYMENTS\n* ALBIREO PHARMA INC - ELOBIXIBAT APPROVED IN JAPAN FOR TREATMENT OF CHRONIC CONSTIPATION\n* ALBIREO PHARMA - JAPAN‘S MINISTRY OF HEALTH, LABOR & WELFARE APPROVED NEW DRUG APPLICATION FOR ELOBIXIBAT FOR TREATMENT OF CHRONIC CONSTIPATION IN JAPAN\n* ALBIREO PHARMA INC - APPROVAL OF ELOBIXIBAT IN JAPAN TRIGGERS PAYMENTS TO ALBIREO SUBSIDIARY ELOBIX AB FROM EA PHARMA CO LTD\n* ALBIREO PHARMA - CO ‍EXPECTS TO INITIATE A PLANNED PHASE 3 STUDY OF A4250 BY SPRING OF 2018​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-19T21:12:00.000+02:00",
    "crawled": "2018-01-20T17:32:33.018+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "albireo",
        "pharma",
        "inc",
        "albireo",
        "receive",
        "million",
        "nondilutive",
        "cash",
        "payment",
        "albireo",
        "pharma",
        "inc",
        "elobixibat",
        "approved",
        "japan",
        "treatment",
        "chronic",
        "constipation",
        "albireo",
        "pharma",
        "japan",
        "ministry",
        "health",
        "labor",
        "welfare",
        "approved",
        "new",
        "drug",
        "application",
        "elobixibat",
        "treatment",
        "chronic",
        "constipation",
        "japan",
        "albireo",
        "pharma",
        "inc",
        "approval",
        "elobixibat",
        "japan",
        "trigger",
        "payment",
        "albireo",
        "subsidiary",
        "elobix",
        "ab",
        "ea",
        "pharma",
        "co",
        "ltd",
        "albireo",
        "pharma",
        "co",
        "initiate",
        "planned",
        "phase",
        "study",
        "a4250",
        "spring",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}